Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13170MR)

This product GTTS-WQ13170MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13170MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6464MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ5219MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ15374MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ13942MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ15783MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ7392MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ11933MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ2991MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW